The global dilated cardiomyopathy market size was estimated to be USD 422.6 million in 2023 and is expected to reach USD 652.0 million by 2034 with a CAGR of 4.02% during the forecast period 2024-2034. The rising prevalence of heart failure, growing awareness of DCM, rising government initiatives, development of novel therapies, technological advancements, and collaborations and partnerships will drive the market growth.
Heart failure is mostly caused by DCM, which accounts for 30-40% of cases worldwide. Numerous reasons, such as aging populations, unhealthy lifestyles, and the increased burden of chronic illnesses like diabetes and obesity, are to blame for the rising prevalence of heart failure. For instance, Novartis AG presented promising Phase 3 results in December 2023 on the reduction of hospitalizations for heart failure among patients with preserved ejection fraction (HFpEF) and DCM. The medication Entresto (sacubitril/valsartan).
By drug class, the angiotensin-converting enzyme (ACE) inhibitors segment accounted for the highest revenue-grossing segment in the global dilated cardiomyopathy market in 2023 owing to the widespread adoption of ACE inhibitors as a primary therapeutic intervention for Dilated Cardiomyopathy. This class of medications, including widely prescribed drugs like enalapril, lisinopril, and ramipril, demonstrated efficacy in managing the condition by inhibiting the angiotensin-converting enzyme, thereby reducing the production of angiotensin II. For instance, in August 2023, Pfizer Inc. presented findings at the European Society of Cardiology Congress that suggested Tafamidis (Vyndaqel) may be able to improve exercise capacity and quality of life in individuals with DCM. Additionally, the angiotensin II receptor blockers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of their efficacy and tolerability in the management of Dilated Cardiomyopathy, coupled with a rising preference for alternative therapeutic options.
By treatment type, the medication segment accounted for the highest revenue-grossing segment in the global dilated cardiomyopathy market in 2023 owing to the increased demand for a diverse range of pharmaceutical interventions, including beta-blockers, diuretics, anticoagulants, and other medications, for the comprehensive management of Dilated Cardiomyopathy. For instance, in August 2023, the Bristol Myers Squibb Company started a Phase 2 study for BMS-986158, a novel investigational small molecule that may possibly be used to treat DCM. The trial was initiated for the treatment of heart failure with preserved ejection fraction (HFpEF). Additionally, the implantable devices segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased adoption of advanced and innovative technologies for the management of Dilated Cardiomyopathy, with implantable devices offering significant therapeutic benefits.
By route of administration, the oral segment accounted for the highest revenue-grossing segment in the global dilated cardiomyopathy market in 2023 owing to the convenience and widespread patient acceptance of oral medications, particularly in the form of tablets and capsules, for the management of Dilated Cardiomyopathy. For instance, in July 2023, MK-6776, a new experimental inhibitor of sGC stimulator (sGC-ST), presented encouraging Phase 2 results that suggested the treatment of HFpEF and maybe DCM. Additionally, the parenteral segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased focus on rapid and targeted drug delivery, especially in acute and critical situations associated with Dilated Cardiomyopathy, where parenteral administration offers quicker onset of action and precise dosage control.
By distribution channel, the hospital pharmacy segment accounted for the highest revenue-grossing segment in the global dilated cardiomyopathy market in 2023 owing to the central role of hospitals in the diagnosis, treatment, and management of Dilated Cardiomyopathy, with hospital pharmacies serving as key distribution points for a wide range of medications and therapeutic interventions. For instance, Johnson & Johnson announced in April 2023 the start of the Phase 2b study of ARNI-1901, a next-generation ARNI candidate with potential uses in DCM, for the treatment of heart failure. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend of digital healthcare adoption, improved accessibility, and the convenience offered by online pharmacies in catering to the evolving needs of patients seeking Dilated Cardiomyopathy medications.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of Dilated Cardiomyopathy, well-established healthcare infrastructure, and a robust research and development landscape, facilitating the continuous introduction of advanced therapeutic interventions and technologies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of cardiovascular diseases, including Dilated Cardiomyopathy, a rapidly expanding geriatric population, and increasing healthcare infrastructure and investments. For instance, in September 2023, Amgen Inc. presented findings at the European Society of Cardiology Congress that suggested omecamtiv mecarbil (Myocampa) may have the potential to improve cardiac function and exercise capacity in individuals with DCM.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Heart failure is mostly caused by DCM, which accounts for 30-40% of cases worldwide. Numerous reasons, such as aging populations, unhealthy lifestyles, and the increased burden of chronic illnesses like diabetes and obesity, are to blame for the rising prevalence of heart failure. For instance, Novartis AG presented promising Phase 3 results in December 2023 on the reduction of hospitalizations for heart failure among patients with preserved ejection fraction (HFpEF) and DCM. The medication Entresto (sacubitril/valsartan).
By drug class, the angiotensin-converting enzyme (ACE) inhibitors segment accounted for the highest revenue-grossing segment in the global dilated cardiomyopathy market in 2023 owing to the widespread adoption of ACE inhibitors as a primary therapeutic intervention for Dilated Cardiomyopathy. This class of medications, including widely prescribed drugs like enalapril, lisinopril, and ramipril, demonstrated efficacy in managing the condition by inhibiting the angiotensin-converting enzyme, thereby reducing the production of angiotensin II. For instance, in August 2023, Pfizer Inc. presented findings at the European Society of Cardiology Congress that suggested Tafamidis (Vyndaqel) may be able to improve exercise capacity and quality of life in individuals with DCM. Additionally, the angiotensin II receptor blockers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of their efficacy and tolerability in the management of Dilated Cardiomyopathy, coupled with a rising preference for alternative therapeutic options.
By treatment type, the medication segment accounted for the highest revenue-grossing segment in the global dilated cardiomyopathy market in 2023 owing to the increased demand for a diverse range of pharmaceutical interventions, including beta-blockers, diuretics, anticoagulants, and other medications, for the comprehensive management of Dilated Cardiomyopathy. For instance, in August 2023, the Bristol Myers Squibb Company started a Phase 2 study for BMS-986158, a novel investigational small molecule that may possibly be used to treat DCM. The trial was initiated for the treatment of heart failure with preserved ejection fraction (HFpEF). Additionally, the implantable devices segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased adoption of advanced and innovative technologies for the management of Dilated Cardiomyopathy, with implantable devices offering significant therapeutic benefits.
By route of administration, the oral segment accounted for the highest revenue-grossing segment in the global dilated cardiomyopathy market in 2023 owing to the convenience and widespread patient acceptance of oral medications, particularly in the form of tablets and capsules, for the management of Dilated Cardiomyopathy. For instance, in July 2023, MK-6776, a new experimental inhibitor of sGC stimulator (sGC-ST), presented encouraging Phase 2 results that suggested the treatment of HFpEF and maybe DCM. Additionally, the parenteral segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased focus on rapid and targeted drug delivery, especially in acute and critical situations associated with Dilated Cardiomyopathy, where parenteral administration offers quicker onset of action and precise dosage control.
By distribution channel, the hospital pharmacy segment accounted for the highest revenue-grossing segment in the global dilated cardiomyopathy market in 2023 owing to the central role of hospitals in the diagnosis, treatment, and management of Dilated Cardiomyopathy, with hospital pharmacies serving as key distribution points for a wide range of medications and therapeutic interventions. For instance, Johnson & Johnson announced in April 2023 the start of the Phase 2b study of ARNI-1901, a next-generation ARNI candidate with potential uses in DCM, for the treatment of heart failure. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend of digital healthcare adoption, improved accessibility, and the convenience offered by online pharmacies in catering to the evolving needs of patients seeking Dilated Cardiomyopathy medications.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of Dilated Cardiomyopathy, well-established healthcare infrastructure, and a robust research and development landscape, facilitating the continuous introduction of advanced therapeutic interventions and technologies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of cardiovascular diseases, including Dilated Cardiomyopathy, a rapidly expanding geriatric population, and increasing healthcare infrastructure and investments. For instance, in September 2023, Amgen Inc. presented findings at the European Society of Cardiology Congress that suggested omecamtiv mecarbil (Myocampa) may have the potential to improve cardiac function and exercise capacity in individuals with DCM.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Drug Class, Treatment Type, Route of Administration, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Dilated Cardiomyopathy Market Report 2023 - 2034
Dilated Cardiomyopathy Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Mn)
- Angiotensin-converting enzyme (ACE) Inhibitors
- Beta-blockers
- Aldosterone antagonists
- Angiotensin II Receptor Blockers
- Others
Dilated Cardiomyopathy Market Analysis & Forecast by Treatment Type 2023 - 2034 (Revenue USD Mn)
- Medication
- Implantable Devices
- Heart Pumps
- Cardioverter-Defibrillators
- Others
Dilated Cardiomyopathy Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Mn)
- Oral
- Parenteral
- Others
Dilated Cardiomyopathy Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Mn)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Dilated Cardiomyopathy Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Mn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Dilated Cardiomyopathy Market: Drug Class Estimates & Trend Analysis
8. Dilated Cardiomyopathy Market: Treatment Type Estimates & Trend Analysis
9. Dilated Cardiomyopathy Market: Route of Administration Estimates & Trend Analysis
10. Dilated Cardiomyopathy Market: Distribution Channel Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Dilated Cardiomyopathy Market
13. Europe Global Dilated Cardiomyopathy Market
14. Asia Pacific Global Dilated Cardiomyopathy Market
15. Latin America Global Dilated Cardiomyopathy Market
16. MEA Global Dilated Cardiomyopathy Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- AstraZeneca PLC
- Amgen Inc.
- Bayer AG
- Sanofi S.A.
- Eli Lilly and Company
- Abbott Laboratories
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline plc
- Mylan N.V. (now part of Viatris Inc.)
- Roche Holding AG.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 422.6 Million |
| Forecasted Market Value ( USD | $ 652 Million |
| Compound Annual Growth Rate | 4.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
